Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting

Teresa Zimmers, Yanling Jiang, Meijing Wang, Tiffany W. Liang, Joseph E. Rupert, Ernie D. Au, Francesco E. Marino, Marion E. Couch, Leonidas Koniaris

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Growth differentiation factor 11 (GDF11), a TGF-beta superfamily member, is highly homologous to myostatin and essential for embryonic patterning and organogenesis. Reports of GDF11 effects on adult tissues are conflicting, with some describing anti-aging and pro-regenerative activities on the heart and skeletal muscle while others opposite or no effects. Herein, we sought to determine the in vivo cardiac and skeletal muscle effects of excess GDF11. Mice were injected with GDF11 secreting cells, an identical model to that used to initially identify the in vivo effects of myostatin. GDF11 exposure in mice induced whole body wasting and profound loss of function in cardiac and skeletal muscle over a 14-day period. Loss of cardiac mass preceded skeletal muscle loss. Cardiac histologic and echocardiographic evaluation demonstrated loss of ventricular muscle wall thickness, decreased cardiomyocyte size, and decreased cardiac function 10 days following initiation of GDF11 exposure. Changes in skeletal muscle after GDF11 exposure were manifest at day 13 and were associated with wasting, decreased fiber size, and reduced strength. Changes in cardiomyocytes and skeletal muscle fibers were associated with activation of SMAD2, the ubiquitin–proteasome pathway and autophagy. Thus, GDF11 over administration in vivo results in cardiac and skeletal muscle loss, dysfunction, and death. Here, serum levels of GDF11 by Western blotting were 1.5-fold increased over controls. Although GDF11 effects in vivo are likely dose, route, and duration dependent, its physiologic changes are similar to myostatin and other Activin receptors ligands. These data support that GDF11, like its other closely related TGF-beta family members, induces loss of cardiac and skeletal muscle mass and function.

Original languageEnglish (US)
Article number48
JournalBasic Research in Cardiology
Volume112
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Growth Differentiation Factors
Myocardium
Skeletal Muscle
Myostatin
Cardiac Myocytes
Transforming Growth Factor beta
Activin Receptors
Organogenesis
Skeletal Muscle Fibers
Autophagy

Keywords

  • Aging
  • Atrophy
  • Autophagy
  • Cachexia
  • Cardiac function
  • Cardiac hypertrophy
  • GDF-11
  • GDF11
  • Growth/differentiation factor-11
  • Myostatin
  • SMAD2
  • Wasting

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. / Zimmers, Teresa; Jiang, Yanling; Wang, Meijing; Liang, Tiffany W.; Rupert, Joseph E.; Au, Ernie D.; Marino, Francesco E.; Couch, Marion E.; Koniaris, Leonidas.

In: Basic Research in Cardiology, Vol. 112, No. 4, 48, 01.07.2017.

Research output: Contribution to journalArticle

Zimmers, Teresa ; Jiang, Yanling ; Wang, Meijing ; Liang, Tiffany W. ; Rupert, Joseph E. ; Au, Ernie D. ; Marino, Francesco E. ; Couch, Marion E. ; Koniaris, Leonidas. / Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. In: Basic Research in Cardiology. 2017 ; Vol. 112, No. 4.
@article{f2e3eec7cb8343df89a78e3144c2b069,
title = "Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting",
abstract = "Growth differentiation factor 11 (GDF11), a TGF-beta superfamily member, is highly homologous to myostatin and essential for embryonic patterning and organogenesis. Reports of GDF11 effects on adult tissues are conflicting, with some describing anti-aging and pro-regenerative activities on the heart and skeletal muscle while others opposite or no effects. Herein, we sought to determine the in vivo cardiac and skeletal muscle effects of excess GDF11. Mice were injected with GDF11 secreting cells, an identical model to that used to initially identify the in vivo effects of myostatin. GDF11 exposure in mice induced whole body wasting and profound loss of function in cardiac and skeletal muscle over a 14-day period. Loss of cardiac mass preceded skeletal muscle loss. Cardiac histologic and echocardiographic evaluation demonstrated loss of ventricular muscle wall thickness, decreased cardiomyocyte size, and decreased cardiac function 10 days following initiation of GDF11 exposure. Changes in skeletal muscle after GDF11 exposure were manifest at day 13 and were associated with wasting, decreased fiber size, and reduced strength. Changes in cardiomyocytes and skeletal muscle fibers were associated with activation of SMAD2, the ubiquitin–proteasome pathway and autophagy. Thus, GDF11 over administration in vivo results in cardiac and skeletal muscle loss, dysfunction, and death. Here, serum levels of GDF11 by Western blotting were 1.5-fold increased over controls. Although GDF11 effects in vivo are likely dose, route, and duration dependent, its physiologic changes are similar to myostatin and other Activin receptors ligands. These data support that GDF11, like its other closely related TGF-beta family members, induces loss of cardiac and skeletal muscle mass and function.",
keywords = "Aging, Atrophy, Autophagy, Cachexia, Cardiac function, Cardiac hypertrophy, GDF-11, GDF11, Growth/differentiation factor-11, Myostatin, SMAD2, Wasting",
author = "Teresa Zimmers and Yanling Jiang and Meijing Wang and Liang, {Tiffany W.} and Rupert, {Joseph E.} and Au, {Ernie D.} and Marino, {Francesco E.} and Couch, {Marion E.} and Leonidas Koniaris",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s00395-017-0639-9",
language = "English (US)",
volume = "112",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "4",

}

TY - JOUR

T1 - Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting

AU - Zimmers, Teresa

AU - Jiang, Yanling

AU - Wang, Meijing

AU - Liang, Tiffany W.

AU - Rupert, Joseph E.

AU - Au, Ernie D.

AU - Marino, Francesco E.

AU - Couch, Marion E.

AU - Koniaris, Leonidas

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Growth differentiation factor 11 (GDF11), a TGF-beta superfamily member, is highly homologous to myostatin and essential for embryonic patterning and organogenesis. Reports of GDF11 effects on adult tissues are conflicting, with some describing anti-aging and pro-regenerative activities on the heart and skeletal muscle while others opposite or no effects. Herein, we sought to determine the in vivo cardiac and skeletal muscle effects of excess GDF11. Mice were injected with GDF11 secreting cells, an identical model to that used to initially identify the in vivo effects of myostatin. GDF11 exposure in mice induced whole body wasting and profound loss of function in cardiac and skeletal muscle over a 14-day period. Loss of cardiac mass preceded skeletal muscle loss. Cardiac histologic and echocardiographic evaluation demonstrated loss of ventricular muscle wall thickness, decreased cardiomyocyte size, and decreased cardiac function 10 days following initiation of GDF11 exposure. Changes in skeletal muscle after GDF11 exposure were manifest at day 13 and were associated with wasting, decreased fiber size, and reduced strength. Changes in cardiomyocytes and skeletal muscle fibers were associated with activation of SMAD2, the ubiquitin–proteasome pathway and autophagy. Thus, GDF11 over administration in vivo results in cardiac and skeletal muscle loss, dysfunction, and death. Here, serum levels of GDF11 by Western blotting were 1.5-fold increased over controls. Although GDF11 effects in vivo are likely dose, route, and duration dependent, its physiologic changes are similar to myostatin and other Activin receptors ligands. These data support that GDF11, like its other closely related TGF-beta family members, induces loss of cardiac and skeletal muscle mass and function.

AB - Growth differentiation factor 11 (GDF11), a TGF-beta superfamily member, is highly homologous to myostatin and essential for embryonic patterning and organogenesis. Reports of GDF11 effects on adult tissues are conflicting, with some describing anti-aging and pro-regenerative activities on the heart and skeletal muscle while others opposite or no effects. Herein, we sought to determine the in vivo cardiac and skeletal muscle effects of excess GDF11. Mice were injected with GDF11 secreting cells, an identical model to that used to initially identify the in vivo effects of myostatin. GDF11 exposure in mice induced whole body wasting and profound loss of function in cardiac and skeletal muscle over a 14-day period. Loss of cardiac mass preceded skeletal muscle loss. Cardiac histologic and echocardiographic evaluation demonstrated loss of ventricular muscle wall thickness, decreased cardiomyocyte size, and decreased cardiac function 10 days following initiation of GDF11 exposure. Changes in skeletal muscle after GDF11 exposure were manifest at day 13 and were associated with wasting, decreased fiber size, and reduced strength. Changes in cardiomyocytes and skeletal muscle fibers were associated with activation of SMAD2, the ubiquitin–proteasome pathway and autophagy. Thus, GDF11 over administration in vivo results in cardiac and skeletal muscle loss, dysfunction, and death. Here, serum levels of GDF11 by Western blotting were 1.5-fold increased over controls. Although GDF11 effects in vivo are likely dose, route, and duration dependent, its physiologic changes are similar to myostatin and other Activin receptors ligands. These data support that GDF11, like its other closely related TGF-beta family members, induces loss of cardiac and skeletal muscle mass and function.

KW - Aging

KW - Atrophy

KW - Autophagy

KW - Cachexia

KW - Cardiac function

KW - Cardiac hypertrophy

KW - GDF-11

KW - GDF11

KW - Growth/differentiation factor-11

KW - Myostatin

KW - SMAD2

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=85021391131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021391131&partnerID=8YFLogxK

U2 - 10.1007/s00395-017-0639-9

DO - 10.1007/s00395-017-0639-9

M3 - Article

C2 - 28647906

AN - SCOPUS:85021391131

VL - 112

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 4

M1 - 48

ER -